A superactive insulin: [B10-aspartic acid]insulin(human).
The genetic basis for a case of familial hyperproinsulinemia has been elucidated recently. It involves a single point mutation in the proinsulin gene resulting in the substitution of aspartic acid for histidine-10 of the B chain of insulin. We have synthesized a human insulin analogue, [AspB10]insulin, corresponding to the mutant proinsulin and evaluated its biological activity. [AspB10]Insulin displayed a binding affinity to insulin receptors in rat liver plasma membranes that was 534 +/- 146% relative to the natural hormone. In lipogenesis assays, the synthetic analogue exhibited a potency that was 435 +/- 144% relative to insulin, which is statistically not different from its binding affinity. Reversed-phase HPLC indicated that the synthetic analogue is more apolar than natural insulin. We suggest that the observed properties reflect changes in the conformation of the analogue relative to natural insulin, which result in a stronger interaction with the insulin receptor. Thus, a single substitution of an amino acid residue of human insulin has resulted in a superactive hormone.
Schwartz
G P
GP
Burke
G T
GT
Katsoyannis
P G
PG
D000818:Animals; D001224:Aspartic Acid; D001667:Binding, Competitive; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007328:Insulin / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000378:metabolism; D008053:Lipid Mobilization / Q000187:drug effects; D008297:Male; D011487:Protein Conformation; D051381:Rats; D011972:Receptor, Insulin / Q000378:metabolism*; D012995:Solubility; D013329:Structure-Activity Relationship
D007328:Insulin; D001224:Aspartic Acid; D011972:Receptor, Insulin